Non-Small Cell Lung Cancer Clinical Trials

A trial may study a medicine, an immune-based treatment, a radiation plan, surgery, a test used to select treatment, or a combination. Some trials compare an investigational approach with an established option; others focus on safety, dose, side effects, or how treatment affects a specific tumour feature.

Eligibility can depend on the cancer subtype, stage, previous treatment, biopsy findings, general health, medicines, and organ function. Joining is voluntary. The consent discussion should explain the purpose, visits, tests, possible benefits, known and uncertain risks, and what happens if you decide not to join.

Ask your oncology team whether a trial fits your diagnosis and treatment timing. Bring pathology reports, scan summaries, a medicines list, and questions about travel, appointment frequency, and who will coordinate care. Options may include [Immunotherapy](/treatments/systemic-therapy/immunotherapy/) or [Targeted Therapy](/treatments/systemic-therapy/targeted-therapy/) within or outside a trial, depending on tumour findings.

Do not stop prescribed treatment while exploring a study. The research team should tell you which visits are required, how side effects are reported, and how your care will be handled if the study closes or you withdraw.

Contact your cancer team promptly for new or worsening breathlessness, chest pain, coughing blood, confusion, fainting, fever, or an inability to keep fluids down. If breathing becomes severely difficult, lips look blue, or you cannot stay awake, seek emergency care immediately.

Which trial matches my cancer type and current treatment plan? What is investigational, and what care would I receive outside the trial? Which tests and visits are required? How will side effects be treated? Who should I call after hours?